Zulu
English French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message
Case Categories
Ikesi elifakiwe
I-Innovative Gene Therapy Inikeza Ithemba Elisha Ngeziguli zeSickle Cell kanye ne-Thalassemia

I-Innovative Gene Therapy Inikeza Ithemba Elisha Ngeziguli zeSickle Cell kanye ne-Thalassemia
I-FUCASO: I-Revolutionary Fully-Human BCMA CAR-T Therapy Ngokusebenza Okungaqhathanisiwe Nokuphepha

I-FUCASO: I-Revolutionary Fully-Human BCMA CAR-T Therapy Ngokusebenza Okungaqhathanisiwe Nokuphepha
I-Optic Nerve Injury-03

I-Optic Nerve Injury-03
I-Optic Nerve Injury-02

I-Optic Nerve Injury-02
I-Optic Nerve Injury-01

I-Optic Nerve Injury-01
I-Metastatic melanoma-04

I-Metastatic melanoma-04
Umdlavuza wesibeletho-03

Umdlavuza wesibeletho-03
I-melanoma ye-ocular (ekuqaleni), ilandelwa yizimila zesibindi ze-metastatic-02

I-melanoma ye-ocular (ekuqaleni), ilandelwa yizimila zesibindi ze-metastatic-02
Isigaba esithuthukisiwe somdlavuza we-colorectal-01

Isigaba esithuthukisiwe somdlavuza we-colorectal-01
Umdlavuza we-prostate wezinga eliphezulu ohambisana nama-metastases amaningi amathambo-05

Umdlavuza we-prostate wezinga eliphezulu ohambisana nama-metastases amaningi amathambo-05
01
4.png

I-Acute Lymphoblastic Leukemia(T-ALL)-06

Isiguli: Xiaohong

Ubulili:Owesilisa

Ubudala: iminyaka emi-2

Ubuzwe: IsiShayina

UkuxilongwaI-Acute Lymphoblastic Leukemia (T-ALL)

    Xhumana nathi

    Isiguli sezingane esineminyaka engu-2 ubudala esine-T-ALL sizuza ukuthethelelwa ngemva kokwelashwa kwe-CAR-T kulandela imizuliswano engaphezu kweyishumi yokwelashwa ngamakhemikhali okunamandla.


    U-Xiaohong oneminyaka emibili ubudala waseZhejiang kwatholakala ukuthi une-leukemia ehlobo eledlule. Ngemva kokwelashwa okungaphezu konyaka, i-flow cytometry yathola ukuphindeka, okuholele ekutheni umndeni ufune ukwelashwa kwe-CAR-T immunotherapy esibhedlela i-Lu Daopei.


    Ngo-Agasti 9, 2020, u-Xiaohong wangeniswa esibhedlela sezingane sendawo ngenxa "yomkhuhlane wezinsuku ezintathu." Ukuhlolwa komnkantsha we-MICM kwatholakala ukuthi i-acute lymphoblastic leukemia (T-ALL). Ngemva kwenkambo eyodwa yokwelapha ngamakhemikhali, i-bone marrow morphology yabonisa ukukhululeka okuphelele, futhi i-flow cytometry ayizange ithole amangqamuzana ayingozi angavuthiwe. Ukwelashwa ngamakhemikhali okunamandla okwalandela ngaphezu kwezifundo eziyi-11 kwagcina ukukhululeka okuphelele komnkantsha.


    Ngomhla zi-3 kuSepthemba 2021, ukubhobozwa komnkantsha okulandelanayo kwabonisa ukukhululeka okuphelele ku-morphology, kodwa i-flow cytometry yembula amaseli angama-malignant angama-1.85%. Efuna ukwelashwa okwengeziwe, u-Xiaohong wangeniswa esibhedlela i-Yanda Lu Daopei ngo-September 24. Ngemva kokungeniswa, i-morphology yomnkantsha yayisaxole ngokuphelele, kodwa i-immunophenotyping yabonisa u-0.10% wama-lymphocyte e-T angalungile.


    Uma kucatshangelwa ubudala buka-Xiaohong nokuphikelela kwalesi sifo naphezu kwemizuliswano engaphezu kweshumi yokwelashwa ngamakhemikhali okunamandla, ithimba lezokwelapha ewadini yesibili yomnyango we-hematology lanquma ukuthi u-Xiaohong angabhalisa ocwaningweni lomtholampilo lwe-CD7 CAR-T.


    Ngomhla zingama-30 kuSepthemba 2021, amangqamuzana egazi ajikelezayo aqoqwa ukuze enze isiko lamaseli e-CAR-T. Ngomhla ziyi-10 kuMfumfu, u-Xiaohong wathola i-FC yerejimeni yokwelapha ngamakhemikhali. Ngo-Okthoba 13, ukubhoboza komnkantsha kwabonisa ukuqhuma okungaphansi kuka-5% ku-morphology, futhi i-cytometry yokugeleza ibonise amaseli angama-T angama-0.37% amabi. Ngo-Okthoba 15, amaseli e-CD7 CAR-T aphinde abuyiselwa.


    NgoJanuwari 3 (izinsuku ezingu-20 ngemva kokufakwa kabusha), ukubhobozwa komnkantsha kwabonisa ukukhululeka okuphelele ku-morphology, ngaphandle kwamaseli amadala ayingozi atholwe yi-flow cytometry. Isimo sika-Xiaohong selokhu sizinzile, futhi usedluliselwe emnyangweni wokufakelwa ukuze alungiselele ukufakelwa i-allogeneic hematopoietic stem cell.


    UXiaohong wayengaphansi konyaka owodwa ubudala lapho egula futhi wabekezelela ukwelashwa ngezidakamizwa isikhathi esingaphezu konyaka. Ukuphumelela ngempumelelo kwebhuloho lokufakelwa kabusha ngemva kokwelashwa kwe-CD7 CAR-T kunikeze isikhali esinamandla sokunqoba ngokuphelele lesi sifo.

    4 mm3

    Kusukela ngoJulayi 2015, isibhedlela iLu Daopei siqale ukuhlolwa komtholampilo kwe-CAR AT cell therapy ezifweni zegazi. Njengenye yamayunithi okuqala okuqala ukwelashwa kwamaseli e-CAR-T e-China, iziguli eziyi-1342 sezingene esivivinyweni kuze kube manje, futhi idatha yomtholampilo ikhombisa ukusebenza ngempumelelo okukhulu nokuphepha okulawulekayo. I-CD7 iyi-40 kDa glycoprotein eyingxenye yomndeni omkhulu we-immunoglobulin, futhi i-CD7 evamile iboniswa ikakhulukazi kumaseli T kanye namaseli e-NK kanye nasezigabeni zokuqala zokuhlukaniswa kwamaseli T, B kanye ne-myeloid, futhi ingasebenza njenge-costimulatory receptor ukuxhumana phakathi kwama-lymphocyte T no-B ngesikhathi sokuthuthukiswa kwe-lymphocyte. I-CD7 iwumaka ozinzile endaweni ye-T cell futhi okwamanje ihlolwa njengenoveli okuhloswe ngayo nge-CAR T cell therapy ye-hematological malignancies. Muva nje, esigcemeni sesibili soMnyango We-Hematology esibhedlela saseLudaopei, iziguli ezine ezinezimo eziyinkimbinkimbi zithole imiphumela esobala ngemva kokwelashwa kwe-CD7 CAR-T.

    incazelo2

    Fill out my online form.